This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Hu-alphaD11, PG110, PG-110
Description: Hu-alphaD11 is a fully humanised antibody that binds to Nerve Growth Factor (NGF) with very high affinity. NGF is the prototypical member of the family of neurotrophin growth factors, that are involved in the growth and survival of nervous tissue. Hu-alphaD11 prevents the interaction of NGF with both its receptors, the high-affinity receptor TrKA and the low affinity receptor p75. This interaction plays a key role in pain transduction mechanisms in the adult peripheral nervous system. Hu-alphaD11 does not cross-react with other neurotrophins and exerts its inhibiting activity at lower than equimolar ratios with respect to NGF. The antibody therefore is a highly specific function-blocking molecule that is able to neutralise NGF bioactivity, both in vitro and in vivo. The antibody has been humanized applying Lay Line Genomic's proprietary methodology.
Deal Structure: Hu-alphaD11 was originally developed by Lay Line Genomics (LLG).
PanGenetics and Lay Line Genomics
In December 2006, PanGenetics and LLG jointly announced that the companies entered into a collaboration in the field of therapeutic antibodies for the treatment of pain. Under the terms of the collaboration agreement, LLG granted to PanGenetics exclusive rights to Hu-alphaD11. The companies will work together on the preclinical program and PanGenetics will assume full responsibility for the clinical development and commercialization of Hu-alpha-D11, which will be renamed PG110.
In addition to research funding and an upfront payment, LLG will receive undisclosed milestone payments and royalties on commercial sales.
Abbott and PanGenetics
In November 2009, PanGenetics announced it entered into an agreement with Abbott under which Abbott will acquire the global rights to PG110. The agreement includes an upfront payment of $170 million plus additional...See full deal structure in Biomedtracker
Partners: PanGenetics B.V. Lay Line Genomics S.p.A.
Additional information available to subscribers only: